Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
Zheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3 1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute...
Main Authors: | Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-08-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-no-peer-reviewed-article-OTT |
Similar Items
-
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
by: Shu Y, et al.
Published: (2020-10-01) -
Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
by: Long Xu, et al.
Published: (2021-09-01) -
Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
by: Chen HF, et al.
Published: (2018-11-01) -
A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
by: Mizuha Haraguchi Hashiguchi, et al.
Published: (2021-09-01) -
A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
by: Hiroaki Tachi, et al.
Published: (2020-07-01)